TRGT News Alert Targacept (TRGT) 2.73 12/25/2014 06:29:49

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Targacept (TRGT) 2.73 $TRGT

Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST

LOXO: 13.50 (+0.06), TRGT: 2.73 (+0.08), BOTA: 2.26 (unch), XBI: 182.62 (+3.44), IBB: 299.80 (+5.12), BIOS: 6.37 (unch), RGDO: 0.89 (unch), EXEL: 1.29 (-0.01), AMPH: 11.74 (-0.09)

Targacept Management Increases Urgency And Aims For Q4 Strategic Action
Daniel Ward - at Seeking Alpha - Fri Nov 07, 8:39AM CST

TRGT: 2.73 (+0.08), ASMB: 7.95 (-0.07), PRTK: 37.70 (+1.30)

More on Targacept Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 10:44AM CST

TRGT: 2.73 (+0.08)

Targacept's (TRGT) CEO Dr. Stephen Hill on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 10:32AM CST

TRGT: 2.73 (+0.08)

Targacept (TRGT) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 7:25AM CST

TRGT: 2.73 (+0.08)

Targacept beats by $0.08
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:41AM CST

TRGT: 2.73 (+0.08)

Targacept Reports Third Quarter 2014 Financial Results
Business Wire - Wed Nov 05, 6:35AM CST
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today reported its financial results for the third quarter and nine months ended September 30, 2014.
TRGT: 2.73 (+0.08)

Targacept to Report Third Quarter 2014 Financial Results on November 5, 2014
Business Wire - Wed Oct 29, 7:55AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced that it will report financial results for the third quarter of 2014 on Wednesday, November 5, 2014, before the U.S. financial markets open.
TRGT: 2.73 (+0.08)

Targacept's Nine-Year Association with AstraZeneca to End - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 3:00PM CDT
Targacept (TRGT) announced that AstraZeneca (AZN) has terminated their nine-year old collaborative research and license agreement.
MDVN: 99.23 (+1.23), TRGT: 2.73 (+0.08), AZN: 70.44 (+0.26), LGND: 51.79 (+1.22)

CYB, SLH, DAL, SYNA, GBF, TRGT Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Oct 01, 3:23AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of WisdomTree Dreyfus Chinese Yuan Fund (NYSE:CYB), Solera Holdings Inc (NYSE:SLH), DELTA AIR LINES INC (NYSE AL), Synaptics Inc (NASDAQ:SYNA), iShares Barclays Government/Credit Bond Fund (NYSE:GBF), Targacept Inc (NASDAQ:TRGT) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
GBF: 113.56 (-0.65), TRGT: 2.73 (+0.08), SYNA: 69.57 (+0.11), DAL: 48.05 (+0.92), SLH: 51.13 (+0.04), CYB: 25.11 (-0.01)

Targacept (TRGT) is Oversold: Can It Recover? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 9:47AM CDT
Targacept (TRGT) is Oversold: Can It Recover?
TRGT: 2.73 (+0.08)

Targacept Reports Second Quarter 2014 Financial Results
Business Wire - Wed Aug 06, 6:35AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today reported its financial results for the second quarter and six months ended June 30, 2014.
TRGT: 2.73 (+0.08)

Targacept to Report Second Quarter 2014 Financial Results on August 6, 2014
Business Wire - Wed Jul 30, 7:30AM CDT
Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced it will report financial results for the second quarter of 2014 on Wednesday, August 6, 2014, before the U.S. financial markets open.
TRGT: 2.73 (+0.08)

Hot Stock: Targacept, Shares Drop 25.5% (TRGT)
Comtex SmarTrend(R) - Tue Jul 29, 10:09AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 25.5% to $2.92 on 2.2x average daily volume. Targacept has traded 751,000 shares thus far today, vs. average volume of 345,000 shares per day. The stock has underperformed the Dow (-25.5% to the Dow's 0.3%) and underperformed the S&P 500 (-25.5% to the S&P's 0.1%) during today's trading.
TRGT: 2.73 (+0.08)

Targacept to Discontinue TC-5214 Overactive Bladder Program
Business Wire - Mon Jul 28, 3:35PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company advancing NNR Therapeutics(TM), today announced top-line results from a Phase 2b clinical trial of TC-5214 as a treatment for overactive bladder (OAB). In the trial, the high dose of TC-5214 demonstrated mixed results on the co-primary endpoints by providing a statistically significant reduction in micturition frequency (p=0.033) and an improvement that did not reach statistical significance on episodes of urinary incontinence (p=0.379) per 24 hours, after 12 weeks of treatment. As a consequence of these results, Targacept is discontinuing further development of TC-5214 in OAB.
TRGT: 2.73 (+0.08)

Technical Update, Leadership Appointments, Therapy Approvals, Notifications, and Clinical Trial Results - Analyst Notes on Biogen, Medivation, BioMarin, Acorda and Targacept
PR Newswire - Thu Jul 17, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Medivation, Inc. (NASDAQ: MDVN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Acorda Therapeutics, Inc. (NASDAQ: ACOR) and Targacept, Inc. (NASDAQ: TRGT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4882-100free.
MDVN: 99.23 (+1.23), BIIB: 340.89 (+5.13), BMRN: 88.18 (+0.89), TRGT: 2.73 (+0.08), ACOR: 39.14 (+0.74)

Targacept Down 7.6%, Shares Slide into the Red (TRGT)
Comtex SmarTrend(R) - Tue Jul 15, 11:38AM CDT
Targacept (NASDAQ:TRGT) is one of today's worst performing low-priced stocks, down 7.6% to $4.08 on 1.2x average daily volume. Targacept has traded 318,000 shares thus far today, vs. average volume of 272,000 shares per day. The stock has underperformed the Dow (-7.6% to the Dow's -0.1%) and underperformed the S&P 500 (-7.6% to the S&P's -0.4%) during today's trading.
TRGT: 2.73 (+0.08)

Targacept Phase 2b Clinical Trial in Alzheimer's Disease Does Not Show Superiority of TC-1734 Over Donepezil
Business Wire - Mon Jul 14, 2:06PM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced top-line results from a Phase 2b monotherapy clinical trial of TC-1734 as a treatment for mild to moderate Alzheimer's disease. In the trial, TC-1734 did not meet the objective of showing superiority to donepezil, the marketed medication most often prescribed for Alzheimer's disease, after 52 weeks of treatment. The trial did not include a placebo arm and was not designed to determine whether TC-1734 is equivalent to donepezil. The co-primary endpoints for the study were measures of cognitive function and global function. Consistent with previous clinical results, TC-1734 exhibited a benign safety and tolerability profile.
TRGT: 2.73 (+0.08)

Age Related Memory Impairment Clinical Trials Review, H1, 2014
M2 - Mon Jun 30, 10:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tn8pmb/age_related) has announced the addition of the "Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" report to their offering. Age Related Memory Impairment Global Clinical Trials Review, H1, 2014" provides data on the Age Related Memory Impairment clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Age Related Memory Impairment. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Age Related Memory Impairment. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Age Related Memory Impairment Therapeutics Clinical Trials - Orexo AB - Helicon Therapeutics, Inc. - Dart NeuroScience LLC - Targacept, Inc. - Martek Biosciences Corporation (Inactive) - Lexicon Pharmaceuticals, Inc. - Bayer AG - Allergan, Inc. - Accera, Inc. - Central Drug Research Institute - University of Cincinnati - The University of Arizona - University Hospital, Toulouse - University of California, Los Angeles - University of Southern California - National Institute on Aging - Queen's University - Stanford University - University of Florida For more information visit http://www.researchandmarkets.com/research/tn...ge_related
AGN: 210.12 (+0.95), TRGT: 2.73 (+0.08), LXRX: 0.90 (+0.02)

Targacept Initiates Exploratory Study of TC-6499 in Diabetic Gastroparesis
Business Wire - Wed Jun 25, 7:55AM CDT
Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics(TM), today announced the initiation of a Phase 1/2 exploratory study of TC-6499 as a treatment for gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. TC-6499 is a novel small molecule that modulates the activity of the alpha3beta4 and other neuronal nicotinic receptors (NNRs). The alpha3beta4 NNR is located throughout the gastrointestinal tract and, when modulated, is believed to increase cholinergic tone, which in turn leads to increased motility.
TRGT: 2.73 (+0.08)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Milwaukee County Contract Tests Wisconsin Labor Shift

Updated Category News Views 60

A unanimous first contract in a Milwaukee County department is not the sort of headline that rattles a trading screen, but it can tell you plenty about where the ground is moving. Public safety workers in the county Facilities Department have ratified their first agreement with Teamsters Local 344, according to the union. The vote matters less for any disclosed economic...

Continue Reading
Atalanta Takes Formal Verification Into Critical Systems

Updated Category News Views 479

A week of bewildering infrastructure failures is a nasty time to discover nobody can explain the machinery. That was the backdrop for Atalanta CEO and co-founder Anjana Rajan at the National Academies of Sciences, Engineering, and Medicine's Cyber Resilience Forum, which concluded November 20 after two days in Washington. Her central point deserves more attention than the...

Continue Reading
Clear Aligner Results Depend on Discipline, Not Hype

Updated Category News Views 115

A Clear Tray Is Not a Magic Wand Transparent orthodontic trays sell a wonderfully tidy idea: straighten teeth without the metal-and-wire routine, take them out to eat, and carry on. Fair enough. But the useful message from Dr. Theresa Trapp is the part nobody should glide past: clear aligners are a treatment plan, not a cosmetic shortcut bought with good intentions....

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 90

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
E-Rate Risk and Data Center Rules Demand Attention

Updated Category News Views 71

America’s digital plumbing is getting squeezed at both ends: the public connections nobody notices until they fail, and the industrial-scale computing boom everybody suddenly wants built yesterday. Connected Nation’s two bonus podcast episodes from the Broadband Nation Expo in New Orleans put those pressures side by side, and it is a more useful pairing than it may...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 95

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 67

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 107

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading
North Richland Hills Bets on Its Visitor Momentum Now

Updated Category News Views 65

A crowded family attraction map is a nice problem for a Texas city to have, and North Richland Hills is trying to turn that pile of assets into a cleaner regional tourism machine. On Nov. 20, 2026, the city introduced “The Place You Never Outgrow,” its first destination-marketing campaign, built with Flat Five Marketing. This is not a stock story in the usual...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 119

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading

Top 5 Most Recently Viewed Articles

CEO of Cogent Communications to Showcase Company Updates

Updated Category News Views 112

Cogent Communications' CEO Will Share Insights at Key Conferences Cogent Communications Holdings, Inc. (NASDAQ: CCOI), recognized as one of the world's premier Internet service providers, has exciting news to share. Dave Schaeffer, the Chief Executive Officer, is set to present at two significant upcoming conferences, demonstrating leadership in the connectivity space....

Continue Reading
AnteraCapital 365 Unmasked: The Truth Behind Fraudulent Claims

Updated Category News Views 338

Understanding the Fraud of AnteraCapital 365 Be an informed investor – protect yourself against fraudulent schemes. The Canadian Investment Regulatory Organization (CIRO) has issued a warning regarding AnteraCapital 365. This fraudulent firm operates on multiple websites claiming to be associated with legitimate organizations, specifically, SIG North Trading, ULC. It is...

Continue Reading
Understanding the Liberty Broadband and Charter Merger Insights

Updated Category News Views 309

Rowley Law PLLC Conducts Investigation into Liberty Broadband Recently, Rowley Law PLLC has announced an investigation related to proposed acquisition activities involving Liberty Broadband Corporation (NASDAQ: LBRDA). This scrutiny comes amid news that Charter Communications, Inc. (NASDAQ: CHTR) intends to acquire Liberty Broadband. This proposed merger is set to impact...

Continue Reading
C3.ai Investors Urged to Act Now for Class Action Lawsuit

Updated Category News Views 198

C3.ai Investors Face Class Action Lawsuit The recent developments regarding C3.ai, Inc. (NYSE: AI) are significant for investors who have faced substantial losses. The former Attorney General of Louisiana, Charles C. Foti, Jr., alongside Kahn Swick & Foti, LLC, has reached out to stakeholders, reminding them of an impending deadline related to a class action lawsuit....

Continue Reading
JW Michaels Shares Insights on Salary Trends in Finance

Updated Category News Views 311

Understanding Executive Compensation in Financial Services Every year, companies and organizations strive to understand the nuances of compensation within the financial sector. JW Michaels & Co. recently released its latest Financial Services Market Data Report, offering valuable insights into executive remuneration practices for top-tier positions. This comprehensive...

Continue Reading